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ABSTRACT
In December 2019, a working group of the European Academy of Microbiology assembled to discuss various aspects of
vaccines and vaccinations. The meeting was organised by Jörg Hacker and Eliora Z. Ron and took place in the offices of the
Leopoldina (German National Academy of Sciences Leopoldina). Several important issues were addressed and a major part
of the discussion focused on the need to develop new vaccines, especially to protect against pathogens that constitute a
pandemic threat. Following the rapid and unpredicted spread of COVID-19 in the first seven months of 2020, the need to
develop vaccines for pandemic viruses rapidly has been clearly established. Thus, this paper will concentrate on points that
were highlighted by the recent COVID-19 pandemic and lessons learnt therefrom.
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THE VALUE OF VACCINES
Introduction
Infectious diseases continue to be a major factor in the devel-
opment of health policy. Approximately 20% of all deaths
worldwide are due to infections (Roth et al. 2018). One of the
greatest public health achievements has been the development
of preventive vaccination. Vaccines are the most cost-effective
preventative measure in infectious medicine and have made
a significant contribution to the containment of infectious
diseases, helping to prevent up to 3 million deaths each year
(UNICEF 2019). In light of their low risk and excellent cost-to-
benefit ratio, vaccines have helped consolidate the concept of
‘global public health’, which is, in theory at least, applicable to
any population at any latitude. The World Health Organization
(WHO) was able to certify the eradication of smallpox in 1980,
encouraging it and other non-governmental organisations to
engage in a similar worldwide program to eradicate poliomyeli-
tis. In addition, diphtheria, tetanus, rabies, typhoid fever, severe
forms of pediatric tuberculosis, whooping cough, measles,
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rubella, mumps, hepatitis B and some invasive infections by
encapsulated bacterial pathogens such as Neisseria meningitidis,
Haemophilus influenzae and Streptococcus pneumoniae could, in
principle, be added to the list of controllable if not eliminable
infectious diseases. Today, however, almost all countries face
problems with insufficient vaccination coverage due to various
threats, such as civil strife or the opposition in some quarters
to vaccination or the under-vaccination of vulnerable groups.
In 2019, WHO placed vaccination hesitancy on its top 10 list of
global health threats (WHO 2020b).
While vaccines are one of the most important weapons
in the arsenal for combating infectious disease, other impor-
tant elements of disease prevention and control should be nei-
ther forgotten nor ignored. These include, in particular, clean
water, good hygiene and specific infection control measures. In
terms of individual therapy, the use of antimicrobials (antibiotics
and antivirals) also needs to be mentioned. The importance of
these measures is illustrated, for example, by the Black Death,
which raged throughout Europe between 1347 and 1351, and was
responsible for wiping out between 30 and 50% of the popula-
tion. The use of whole genome sequencing to understand what
made the 14th-century causative agent, Yersinia pestis, so viru-
lent came to the surprising conclusion that it was virtually iden-
tical (97 single nucleotide polymorphisms) to strains in circula-
tion today and that it causes only minor outbreaks (Bos et al.
2011; Callaway 2011; Feldman et al. 2016).
Clearly, social conditions, such as nutrition, lifestyle, access
to medical facilities and sanitation, combine to limit the infec-
tion and transmission of this and other microbes. The impor-
tance of sanitation is illustrated by the work of three 19th-
century pioneers: Joseph Bazalgette, who built the London
sewage system, John Snow, regarded as the father of epidemiol-
ogy for tracing the source of a cholera outbreak in Soho, London,
and Ignaz Semmelweis, the Hungarian physician responsible for
developing antiseptic procedures that are now central to infec-
tion control in healthcare and other public facilities (Snow 1856;
Semmelweis 1974; Lane, Blum and Fee 2010).
THE HISTORY OF VACCINATION
Disease prevention through vaccination began more than 200
years ago in Europe with Edward Jenner and the development of
the smallpox vaccine in 1796 (Riedel 2005). However, long before
the 18th century, it was common practice in China and the Mid-
dle East to infect people not suffering from smallpox by inoc-
ulating the secretion from the pustules of smallpox patients.
Most of these inoculated individuals fell ill comparatively eas-
ily and were protected from smallpox for the rest of their lives.
However, inevitably, some individuals died from the inocula-
tion itself (Boylston 2012). The English country doctor Edward
Jenner developed a less dangerous vaccination method (Mor-
gan and Parker 2007). He had observed that farm workers who
had already been infected with the harmless cowpox were often
spared the dangerous, usually fatal human pox. He concluded
that people could be protected from the disease by a targeted
infection with cowpox in the form of a vaccination. In order to
prove a causal connection, he carried out the following deci-
sive experiment in 1796: he vaccinated an eight-year-old boy,
who had previously been spared from smallpox, with the pus-
tule secretion of a milk maid suffering from cowpox, whereupon
the boy fell ill with a mild infection. Six weeks later, he inoc-
ulated the boy with smallpox secretion, and, as expected, the
boy did not fall ill with the disease. Edward Jenner published
his results two years later in a report that became a landmark
paper in the Annals of Medicine. His statement ‘that the cowpox
protects the human constitution from the infection of smallpox’
laid the foundation for modern vaccinology (Jenner). His method
underwent medical and technological changes over the next 200
years, and eventually resulted in the eradication of smallpox in
1980 (Breman, Arita and WHO 1980).
The first compulsory vaccination requirements were passed
in Italy in 1806, France in 1810, and in Sweden in 1816 (Salmon
et al. 2006). In the UK, Parliamentary Acts of 1853 and 1867 made
the vaccination of children against smallpox compulsory, and
were backed by fines and even imprisonment. However, distrust
of the medical profession and governments was a major factor
fuelling resistance to vaccination, and in the late 19th century,
thousands took to the streets in England demanding the repeal
of the Vaccination Acts. Following mass protests in the 1880s,
arguing that individual rights were being sacrificed for the bene-
fits of the population as a whole, a Vaccination Act of 1898 intro-
duced an opt-out clause based on conscientious objection (El
Amin et al. 2012).
The next advance in the development of vaccines, using the
principle of attenuation, was invented by Louis Pasteur, nearly
a century after Edward Jenner’s experiments. In 1880, Pasteur
succeeded in producing a vaccine against cholera in chickens
caused by Pasteurella multocida (Pasteur 1880). Pasteur’s pupil
Émile Roux was able to prove the active principle of this immune
defence by blood tests. Only one year later, an effective vaccine
against anthrax was developed (Lombard, Pastoret and Moulin
2007). In 1884, Pasteur, for the first time, cured a patient infected
with the pathogen causing rabies by means of a successful vacci-
nation (Bardenave 2003). This contained material obtained from
infected rabbit brain attenuated by drying, an unreliable pro-
cess, and vaccines prepared in this way frequently caused seri-
ous side effects. Nevertheless, Pasteur’s attenuation principle
marked the beginning of the process by which laboratory sci-
ence would transform vaccine development during the course
of the subsequent century.
Between 1890 and 1950, bacterial vaccine development pro-
liferated, based on the discovery that immunogenicity could
be retained if bacteria were killed by heat or chemical treat-
ment (vaccines against typhoid, plague, cholera and pertussis),
or by administration of inactivated bacterial toxin (e.g. diphthe-
ria, tetanus) (Behring and Kitasato 1890). In 1954, a further break-
through was achieved with the discovery that cells could be cul-
tured in vitro and used as substrates for viral growth. This dis-
covery would spawn an entirely new generation of vaccines—of
killed or attenuated viruses—including polio, measles, mumps,
rubella, adenovirus and others (Enders, Weller and Robbins 1949;
Salk 1955; Gotschlich, Liu and Artenstein 1969; WHO 2020a). The
polio vaccines (Sabin, Hennessen and Winsser 1954) have elim-
inated polio from most of the world and reduced the number of
reported cases from an estimated 350 000 cases in 1988 to 33 in
2018 (WHO 2020a).
This was the phenomenal 20th-century legacy to global pub-
lic health and the 21st century started at a similar pace with
the development of novel vaccines: an extended spectrum of
polysaccharide conjugates against encapsulated bacteria, vac-
cines against rotavirus diarrhoea and vaccines against onco-
genic papillomavirus promising the elimination of cervical can-
cer and other sexually transmitted tumours in both sexes (Cryz
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2007; Turner et al. 2017). In parallel, ‘universal vaccination’
became increasingly global, thanks to unprecedented coordi-
nated efforts by the WHO Expanded Programme on Immuniza-
tion, national governments, the vaccine industry and philan-
thropic foundations to make vaccines accessible to all children,
regardless of means.
MODERN VACCINOLOGY
Vaccination has been a major advance for healthcare, allow-
ing the eradication and reduction of various infectious dis-
eases. While existing vaccines continue to be improved and dis-
tributed, major pathogens such as human immunodeficiency
virus (HIV) or the causative agent of malaria represent signifi-
cant research challenges that require the development of new
vaccination strategies. An additional challenge—the focus of
this paper—is developing vaccines in preparation for and dur-
ing pandemics. Moreover, vaccine development is a field that
requires constant adaptation in the face of a changing pattern
of infectious diseases, hence a need for better education, com-
munication, and engagement with health professionals and the
public about this sensitive field. Here we identify key elements
of apprehension.
Access to vaccines and vaccination
In various countries, the vaccination coverage is reduced due to
limited access to vaccines and vaccinations. This is relevant not
only to low- and middle-income countries with weak healthcare
infrastructures but also to high-income countries, which do not
always take into consideration the daily life barriers of the pop-
ulation. Easy access to vaccination needs to be accomplished by
barrier-free access.
Demographic changes
In response to public health policies, life expectancy has dou-
bled over the last century and the proportion of the elderly in the
population continues to rise. Elderly people are more suscepti-
ble to infectious diseases and less responsive to vaccination, as
is clearly shown by their responsiveness to the influenza vaccine
(Franceschi et al. 2017; Demicheli et al. 2018; Levett-Jones 2020).
This growing situation warrants the adaptation of vaccines to
the senescing immune system, thereby introducing a certain
degree of personalisation at the scale of an age-defined popu-
lation. For example, the Sanofi Pasteur Fluzone High-Dose triva-
lent flu vaccine and the Seqirus Fluad quadrivalent flu vaccine
are specifically recommended for the over 65 years old (JAMA,
published online: 2 October 2020) (Monto et al. 2009).
Microbes change and new ones emerge
This is dramatically illustrated by the current worldwide COVID-
19 pandemic. Examples of emerging diseases over the last 20
years include West Nile fever, influenza, severe acute respiratory
syndrome (SARS), Middle East respiratory syndrome coronavirus
(MERS-CoV) and antimicrobial resistant pathogens such as drug-
resistant tuberculosis, gonococcus, extraintestinal Escherichia
coli and Staphylococcus aereus (Cupertino et al. 2020).
Attitudes change
Opposition to vaccination is not new, but the reasons why and
the ways in which sections of the populations have developed
opposition to vaccines have changed. The beginning of the 21st
century was marked by a growing defiance by a small but vocal
proportion of the population against vaccination and a subse-
quent decrease of vaccine coverage in many countries, partic-
ularly in Europe and North America. This decrease brings with
it the threat of a widespread return of infectious diseases (e.g.
measles, whooping cough, diphtheria) whose causative agents
are still circulating in the population. Vaccination is therefore as
much about relationships and trust between society and health
authorities as it is medicine and science. Those actively oppos-
ing vaccination, while a small minority, can have an ampli-
fied view, particularly through online and social media activi-
ties, which offer them a larger forum. Consequently, there is an
urgent need to re-establish confidence in vaccines. The major
issue is to convince young parents of the importance of vacci-
nation, and, in this context, paediatricians and general practi-
tioners have a key role to play. This requires strengthening the
training of medical students and post-graduates in preventive
medicine, risk communication and vaccinology.
Climate and environment change
Climate change and the ongoing change of natural environ-
ments by humans driven by increased urbanisation, global food
production and exploitation of natural resources threatens habi-
tats and reduces biodiversity. These pressures are a major driver
of new zoonotic pathogens that are able to cross from one
species to another. For example, expansion of the geographic
range of the arthropod vectors had a considerable effect on the
spread of arboviruses (Pena-Garcia, McCracken and Christoffer-
son 2017; Sukhralia et al. 2019).
Human behaviour changes
The reduction in travel and shipment costs has resulted in
a significant and unprecedented increase in global trade and
travel. As clearly shown by the COVID-19 pandemic, interna-
tional travel is a major source of the global spread of emerg-
ing infectious diseases, which have the potential to develop into
epidemics and pandemics. The global challenge is to be able to
develop vaccines on a time-scale that is compatible with the
control of pandemic spread or subsequent re-emergences. The
pandemic spread of HIV, and now COVID-19, illustrates the dif-
ficulty of controlling and eliminating an emerging pandemic
without the aid of a vaccine. Similarly, the virulent Ebola epi-
demics in Western Africa have also illustrated that when the
dynamics of the epidemics are particularly robust, controlling
an emergent disease simply by classical technologies (isolation
and attenuation of the pathogen) is not realistic. Here again, only
scientific progress in immunology, microbiology and vaccinol-
ogy, coupled with international cooperation, will help to reduce
the time necessary to conceive, develop and validate a vaccine.
VACCINES IN OUTBREAKS AND PREPARATION
FOR PANDEMICS
Preparing vaccines for potential pandemic outbreaks is com-
plicated and challenging. There are two possible scenarios—an
outbreak by a known pathogen (Ebola, Zika) and a new zoonotic
pathogen (H1N1, swine influenza) (Vincent et al. 2014) or an out-
break by a new virus or an outbreak by a previously unknown
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Figure 1. Stages in vaccine development.
known pathogens, it is conceivable to develop a protective vac-
cine, which will reduce the risk of an epidemic. However, the
challenge here is often mainly financial—developing a vaccine
involves significant costs that have to be offset against their
benefits. It is estimated (Gouglas et al. 2018) that the total cost
of developing a vaccine for an epidemic infectious disease is a
minimum of around 3 billion US dollars (see below). But this
investment may bring little or no benefit if a pandemic does not
develop. For ‘new’ pathogens, such as COVID-19, the develop-
ment may not be fast enough and—also here—there is a risk that
the pandemic is a one-time event that does not return, similar to
the case of the 2002–2004 SARS outbreak. The case for develop-
ing a vaccine protective against COVID-19 is unique because, in
addition to the impact on health, the economic consequences
are so severe. This has resulted in the need for considerable
investment by governments and disease prevention charities.
Together these funds have provided a financial blanket for vac-
cine developers.
As well as being enormously costly, the vaccine development
process is generally lengthy and multidisciplinary. We outline
the main steps needed to develop such a new vaccine and how
this is funded—summarised in Fig. 1. Typically, research on a
given microorganism starts in academia, examining questions
such as disease pathology, transmissibility and characterisation
of the agent in terms of taxonomy, structure, natural history,
growth requirements, animal model development and decipher-
ing immune responses that may lead to the identification of
antigens and possibly correlates of protection. This research
may include the identification of sub-structures, such as individ-
ual proteins or polysaccharides, particularly those at the infec-
tive agent’s surface, that can be used in isolation or in combi-
nation as candidate immunogens. A key question is whether
these antigens display variability among different isolates, both
geographically and over time. Variability may imply the need
for multivalency to be effective [e.g. vaccines against pneumo-
coccus, meningitis, polio, human papillomavirus (HPV), etc.] or
the need for seasonal changing of the vaccine (e.g. influenza).
The vaccine development process then begins in earnest with
the commitment to progress candidate immunogens to first-in-
man studies, using clinical-grade materials prepared under con-
ditions of strict regulatory compliance. The step towards clinical
studies may be done in universities, often using the expertise
and facilities of contract research organisations but is more typ-
ically carried out in industry. These clinical studies involve rig-
orous quality control and testing—for identity, purity, toxicity,
consistency and quantitation. Candidate immunogens may be
presented in various forms, ranging from live-attenuated whole
organisms, killed or inactivated whole organisms, nucleic acid
vaccines, vectored genes encoding the protein antigen of inter-
est through to individual ‘sub-units’ of purified proteins or pro-
tein complexes or free or conjugated polysaccharides. Meth-
ods of delivery are typically intramuscular (IM) or subcutaneous
injection but can be oral or nasal, as is the case with some live-
attenuated vaccines (LAVs).
Development of clinical-grade material allows progression
of the immunogen through the clinical development phases,
which are typically Phase I for safety, Phase II for immuno-
genicity, and phase III for efficacy, large-scale safety and product
consistency, preferably from intended final production facilities.
Eventual approval and licensure require ongoing pharmacovig-
ilance and possibly Phase IV studies for extending the use of
the vaccine. The wide range of product types (killed, LAV, sub-
unit, nucleic acid, etc.) means that generally each new vaccine
requires the development of its own specific technology and
protocols, for production, downstream processing (purification
and optimisation), quality control and even filling and packag-
ing. Typically, each vaccine is produced in a bespoke and dedi-
cated facility, meaning that bioproduction in multiuse facilities
is technically difficult and uncommon. Although there are con-
certed efforts nowadays to develop platform technologies that
can be used for the development and manufacture of a range
of vaccines, and for attempts to shorten the costs and timelines
involved, the research and development (R&D) process outlined
above typically takes 10–15 years and the costs have been var-
iously estimated to be around $800 million but can be signifi-
cantly higher, driven by the scale and complexity of Phase III
studies. In addition, the construction of large-scale manufactur-
ing facilities requires further investment, which may be in the
range of $500 million and the work typically takes four or more
years. This latter investment is often required to be ‘at risk’,
that is to say, it is needed before proof of product and efficacy
has been established, e.g. during Phase II, in order to be ready
to launch the product and meet demand in major markets and
affected areas immediately after licensure.
The cost, long-term commitment, know-how, supply chain
management, etc., make the above scheme in its entirety man-
ageable only by major pharmaceutical companies and only
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including wealthy countries with developed healthcare systems,
and whose uptake will be universal or at least very widespread.
It is normally not possible for companies to make a commit-
ment to spend in excess of $1 billion without an expectation of a
‘return on investment’ through sales of vaccine in the years that
follow. Spending on vaccine projects that will not even return
the cost of development is a recipe for the demise of the industry
and the potential disruption to the supply of existing vaccines.
Also, it is self-evident that the above scheme does not work well
economically for vaccines that are required for very restricted
regions, for vaccines needed only for short periods to address
outbreaks or for vaccines needed only in lower income coun-
tries that cannot afford to pay prices that would ensure a return
on investment. Thus, the business case against the development
of vaccines for diseases such as Ebola, Lassa, Hendra, Zika and
some others on the WHO priority list is not positive.
Fortunately, there are methods and means to enable and
incentivise vaccine development when the business case is lack-
ing. These are often referred to as ‘push-and-pull’ measures.
‘Push’ is where governments, charities, etc., fund early-stage
research in an attempt to secure a proof of concept and thus de-
risk the scientific aspects of the project. ‘Pull’ is structured so
that sales of certain volumes of vaccine at a pre-arranged price
can be agreed between the health authorities and the manufac-
turer ahead of the launch so that revenues in the early years are
guaranteed.
Historically, the most spectacular grassroots, non-industrial
funding of a vaccine project was the March of Dimes, organised
by the National Foundation for Infantile Paralysis (NFIP) founded
by Franklin D. Roosevelt. The US population gave generously
to this mission to provide grants to researchers studying the
poliovirus, culminating in the development of the Salk inacti-
vated polio vaccine and, subsequently, the Sabin live-attenuated
orally administered polio vaccine. More recently, the Bill and
Melinda Gates Foundation announced as its goal ‘to identify,
support, and shape scientific research that can have the most
impact and to accelerate the translation of scientific discoveries
into solutions that improve people’s health and save lives’. This
announcement has provided a serious infusion of funds into
R&D of vaccines targeted at the developing world. Other char-
ities such as the Wellcome Trust, The Hillman Foundation as
well as government-supported institutes have contributed sig-
nificantly to the funding of the fundamental science of vacci-
nology.
Thus far, however, it has been difficult to amass the funding,
from outside the private sector, to complete a vaccine develop-
ment process through Phase III to licensure. A recent notable
exception to this and the heartening success is the development
and production of an Ebola vaccine for use in outbreak control
in Western Africa. This was achieved with significant interna-
tional support and with both philanthropy and know-how sup-
port from the Merck organisation in collaboration with NewLink
Genetics. The Ebola outbreak, however, did illustrate that the
world is ill-equipped to deal with outbreaks that may initially
threaten restricted geographical regions but then may broaden
to much wider geographical regions. These lessons learnt from
the Ebola outbreak were one of the drivers for the creation in
2017 of the Coalition for Epidemic Preparedness Innovations
(CEPI) to develop vaccines against emerging infectious diseases.
CEPI is funded by donations from public, private, philanthropic
and civil society organisations and is supported by the main vac-
cine manufacturers. Originally focused on the WHO’s ‘blueprint
priority diseases’, CEPI has emerged in 2020 as key player in the
race to develop a vaccine against COVID-19.
SOCIAL AND BEHAVIOURAL ASPECTS OF
VACCINATION
To determine possible public reactions to a newly developed
SARS-CoV-2 vaccine, it is helpful to look at vaccines that were
rolled out in response to other disease outbreaks. Interestingly,
a variety of different reactions can be found. In the 1950s, there
was a high demand for the polio vaccine because the risk was
very present. On the other hand, during the 2009 H1N1 ‘swine
flu’ pandemic, the concerns over a new vaccine being rushed or
inadequately tested led to low uptakes in some countries.
Those who are critical of or who are opposed to vaccina-
tion might now be expected to be quiet in the face of a real-
life reminder of a time before vaccines controlled many debil-
itating fatal diseases. However, as the prospect of new vaccines
enters development with a number of candidates in Stage II and
even Stage III trials, the promise of a vaccine against COVID-
19 becomes more concrete. At the same time, the position of
those who oppose vaccination becomes more apparent. Some
celebrities and high-profile personalities have already spoken
out against a possible vaccine. Even more concerning, some of
those who protested against lockdown measures in the USA
and promoted fake news stories about the safety of new vac-
cines have been shown to be members of vaccine-critical groups
(Hotez 2020a, b).
It appears that the heightened stakes of an infectious dis-
ease threat can push certain factions of the population into a
more entrenched, non-science-based position, which includes a
stronger and more vocal opposition to vaccination. There are a
number of reasons why vaccine critiques are especially worried
that their values and beliefs will not be upheld during a global
health crisis. These worries extend from the suspicion and mis-
trust of governments, pharmaceutical companies and interna-
tional organisations across many areas, such as encroachment
into private lives (through surveillance and possible enforce-
ment of vaccines). Moreover, the steady increase in misinforma-
tion and disinformation, and ‘influencers’ offering alternative
‘natural cures’ for COVID-19 that are either ineffective or even
harmful pose additional risks (Pennycook 2020). Scepticism∗∗
about the motivations of the developers of new vaccines and
questions about safety and usefulness could potentially derail
a vaccination campaign as has happened previously. For exam-
ple, in 2017, a rumour about the vaccination making children
infertile halted a government measles and rubella vaccination
campaign in five Indian states (Palanisamy, Gopichandran and
Kosalram 2018).
Even though a vaccine for COVID-19 will go through rigorous
safety and effectiveness tests, a level of apprehension is likely
to exist among the public and in the media about the integrity
of vaccine trials and possible adverse side effects. It is, there-
fore, most important that Phase IV post-marketing studies are
done transparently by governments, to inform the public about
the efficacy in particular risk or target groups, the side effects
and the risks associated with non-vaccination. Health author-
ities and governments will also need to react quickly to false
or misleading information in cooperation with social media and
messaging companies. These companies are aware of their role
against fake news, as shown by the steps taken by the pri-
vate messaging service WhatsApp, which is owned by Facebook.
WhatsApp recently made changes to limit ‘frequent forwards’,
which restricted the number of times that a message can be for-
warded to five (Hern 2020). Further vigilance and interventions
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NEW TECHNOLOGIES AND HOW THEY CAN
PROVIDE A SOLUTION TO NEW THREATS TO
HUMAN HEALTH
Increasing knowledge of chemistry, immunology, microbiology,
molecular biology and structural biology and the access to new
technologies have completely changed the vaccine development
landscape, providing the tools for the development of new, more
effective and safer vaccines.
The discovery that chemical conjugation of a polysaccha-
ride makes the sugar immunogenic and is able to induce a
strong T-cell-dependent response, helping B-cells to produce
high-avidity antibodies and immune memory (Costantino, Rap-
puoli and Berti 2011), was a significant breakthrough. It facili-
tated the development of conjugated vaccines that are effica-
cious for the prevention of diseases, such as Haemophilus influen-
zae type B (Peltola et al. 1977), four meningococcal serogroups
(A, C, W and Y) and up to 21 Streptococcus pneumoniae serotypes,
with many more in pre-clinical and clinical development. The
application of genetic engineering and molecular biology tech-
niques means that antigens can be expressed in heterologous
microorganisms, and this has facilitated the rational design
of immunogenic and safe antigens. The first vaccine to be
designed using genetic engineering technologies was the hep-
atitis B vaccine, in which the gene encoding the main anti-
gen, the viral capsid’s ‘S’ antigen, was cloned and expressed in
a heterologous expression system. The antigen was expressed
in yeast at a very high yield and self-assembled into virion-
like structure resembling the viral coat. This antigen was highly
immunogenic and much safer compared to the previous hep-
atitis B vaccine, in which viral particles devoid of their nucleic
acid were purified from the blood of infected individuals. The
recombinant hepatitis B vaccine is widely used for immunisa-
tion starting from 2 months of age, and in many countries, it
is given within 24 hours from birth. The heterologous expres-
sion system of viral antigens is being applied to many other
viruses, such as the HPV and the herpes zoster virus. Three
HPV vaccines have been registered so far, based on two, four or
nine serotypes expressed as virus-like particles in insects or in
yeast.
Recombinant DNA technologies have been also successful in
the case of bacterial vaccine developments. The first example
was the design of a recombinant non-toxic and immunogenic
pertussis toxin, the main virulence factor of Bordetella pertus-
sis (Marsili et al. 1992). In this case, a mutant pertussis toxin
is produced by an engineered B. pertussis strain, in which the
two codons identified by sequence alignment as being essen-
tial for the adenosine diphosphate (ADP)-ribosylation activity
have been mutagenised. The resulting inactive gene was used
to replace the wild-type gene on the B. pertussis chromosome,
by allelic recombination. The PT9K/129G mutant toxin, puri-
fied from the culture supernatant of the recombinant strain,
has been shown to be safe, able to induce neutralising anti-
bodies and efficacious in clinical trials. The basic principles
for the design of non-toxic forms of bacterial toxin, through
site-directed mutagenesis or expression of only immunogenic
domains, are now routinely applied to the development of other
bacterial toxins as antigens or as carrier proteins for polysaccha-
ride vaccines.
Genetic engineering technologies are now routinely used to
generate rationally designed attenuated bacterial strains. This
approach involves the identification of genes encoding viru-
lence functions and their inactivation to generate non-toxic but
immunogenic strains. The main challenge resides in the ability
to identify bacterial functions, which do not impact on the abil-
ity of the strain to colonise and replicate in the host to induce
an effective immune response while impacting on the strain’s
ability to cause disease. Such approaches have been extensively
applied, mainly to enterotoxigenic pathogens such as Salmonella
enterica subsp. enterica Serovar Typhi, Vibrio cholera and Shigella
strains (Barry and Levine 2019). Although very promising, no
vaccines based on this technology have so far been licensed, sug-
gesting that the right balance between reduced virulence and
immunogenicity continues to be a challenge.
Engineered E. coli strains have been recently used to produce
bio-conjugated polysaccharide vaccine antigens. In this case,
both the polysaccharide and the carrier protein are synthetised
in the E. coli bacteria and conjugated by the PglB oligosaccha-
ryltransferase enzyme (Wacker et al. 2006; Huttner et al. 2017).
This methodology avoids the purification of the separate anti-
gens (the polysaccharide and the carrier protein) and the need
for their subsequent chemical conjugation. Bioconjugates for
Shigella flexneri and extraintestinal E. coli have been tested in a
Phase I clinical trial with promising results (Hatz et al. 2015; Hut-
tner et al. 2017). Additional bio-conjugate vaccines are in pre-
clinical studies.
Gram-negative bacterial strains can also be engineered to
produce high yields of outer membrane vesicles (OMVs), known
to be enriched with outer membrane proteins that represent
ideal vaccine antigens. Strains are engineered through the intro-
duction of chromosomal mutations generating an ‘overbleb-
bing’ phenotype and a less reactogenic lipopolysaccharide (LPS).
OMVs derived from these recombinant strains, also named
GMMAs (generalised module membrane antigens), can be fur-
ther engineered to over-express heterologous antigens and to
form the basis of multivalent vaccines (Berti and Micoli 2020).
The immunogenicity of Shigella sonnei GMMA has been shown
in a Phase I clinical trial in humans (Obiero et al. 2017).
The genomic era has changed the vaccine landscape even
more. Starting from the first genome sequence of a bacte-
rial pathogen, Haemophilus influenzae type B, the number of
sequenced genomes available in the European Bioinformatics
Institute (EBI) and National Center for Biotechnology Informa-
tion (NCBI) databases is of the order of a hundred thousand. The
genome revolution has been possible because of the rapid whole
genome sequencing technologies that allow an entire genome
to be sequenced within minutes and at very low cost. There-
fore, whole genome sequencing is easier than the ‘one-by-one’
sequencing of a few genes of interest and provides a compre-
hensive picture of the sequences responsible for the epidemio-
logical variability and virulence features of a given microorgan-
ism. Moreover, the genome sequence provides access to the anti-
gens that are potentially expressed at all stages of its virulence
cycle. Access to this comprehensive set of information has facil-
itated the introduction of a breakthrough technology referred to
as ‘reverse vaccinology’. The principle is based on the possibility
of screening a genome in silico, using a wide number of bioinfor-
matic tools that can drive the identification of surface-exposed
antigens, a family of proteins that have a high probability to be
efficient targets for antibody recognition. The first success of the
‘reverse-vaccinology’ approach has been the development of the
multivalent meningococcal vaccine, named 4CMenB.
Bioinformatic screening of the meningococcal B genome
strain MC58 resulted in the identification of 600 potential
surface-exposed or secreted antigens. The genes encoding these
potential antigens were amplified and cloned in E. coli on an
expression vector. A total of 350 antigens were successfully puri-
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Figure 2. Development of vaccine in times of COVID-19.
range of in vitro assays (Pizza et al. 2000). Among the 96 new sur-
face antigens, 3 induced antibodies with complement-mediated
bactericidal activity against a variety of meningococcal strains,
a property known to correlate with protection in humans. The
three antigens, combined with the OMVs of an outbreak strain
(the New Zealand strain), are now the basis of a meningococ-
cal vaccine, which is licensed for vaccination starting from 2
months of age in more than 40 countries and for use in ado-
lescents in the USA (Masignani, Pizza and Moxon 2019). The
potential of the ‘reverse-vaccinology’ approach to identify novel
antigens as potential vaccine candidates has subsequently been
demonstrated for a wide range of bacterial pathogens such as
Group A and Group B Streptococcus, Staphylococcus aureus and
extraintestinal E. coli. Many of the newly discovered antigens are
under analysis for their immunological properties in pre-clinical
studies and are expected to be tested in clinical studies in the
near future (Delany, Rappuoli and Seib 2013).
The revolution in the vaccine field brought about by the
genomic era is based around the ability to access genomic data
through an open-source network. For example, a novel virus
can be sequenced overnight, and its genome sequence made
available immediately worldwide. Candidate vaccine proteins
can then be identified and DNA synthesis technology used to
generate the required viral genes, or the whole virus itself, for
subsequent expression in prokaryote or eukaryote production
systems. Once the genome sequence is made publicly available,
genes encoding for the capsid antigens can be synthetised and
cloned in non-pathogenic viruses attenuated in their ability to
replicate in host cells, or in non-replicating viruses. Viral vec-
tors widely used are poxvirus, alphavirus and adenovirus. More
recently, vesicular stomatitis and measles virus were also con-
sidered as promising viral vectors (Lauer, Borrow and Blanchard
2017).
The case of influenza strain H7N9 is a good example of the
power of synthetic biology to accelerate vaccine development.
The genome sequence of H7N9 was made available online by a
Chinese group in March 2013. Researchers at Novartis Vaccines,
in collaboration with the Institute of Synthetic Genomics, used
the sequence data to synthesise the viral genes and insert them
into a viral vector that was then used to infect eukaryotic cells
to produce a recombinant virus. As a result, in just a few days,
the vaccine seeds were ready to be used for manufacturing (Dor-
mitzer et al. 2013). The recombinant viruses could then be used
to infect the target cells, which produce the heterologous viral
antigens and induce strong B- and T-cell responses (Pinschewer
2017).
A recent example of the use of viral vectors relates to the
development of the Ebola vaccine (Tully et al. 2015). The vesic-
ular stomatitis virus (VSV)–Ebola virus (EBOV) vaccine is based
on the Ebola glycoprotein cloned into a VSV and was approved
by the European Medicines Agency (EMA) and US Food and Drug
Administration (FDA) in 2019. The cAD3-EBO Z vaccine is based
on an attenuated version of a chimpanzee adenovirus, genet-
ically engineered to be unable to replicate in humans, and to
express on its surface the Ebola glycoprotein. This vaccine was
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vaccine, in which the human adenovirus serotype 26 (Ad26) is
expressing the Ebola glycoprotein and the MVA-BN (Modified
Vaccinia Virus Ankara—Bavarian Nordic) vaccine vector, was
tested in a prime-boost immunisation regimen. Marketing
authorisation for this vaccine was submitted in 2019.
Synthetic biology is also the basis of another major techno-
logical innovation in which antigen-encoding messenger RNA
(mRNA) acts as a vaccine platform. mRNA is non-infectious,
does not integrate into the chromosome, does not self-replicate
and is naturally degraded by the host cells (Pardi, Hogan and
Weissman 2020). Efficient delivery of mRNA can be achieved
through formulation with carrier molecules such as liposomes,
cationic polymers or nanoemulsion, which increase uptake and
antigen expression. Self-amplifying mRNA (SAM) vaccines are
based on an alphavirus genome, in which the genes encoding
for the RNA replication system are preserved, while the genes
encoding the structural proteins are replaced with the antigen of
interest. The mRNA technology has been applied to a variety of
infectious viral and bacterial pathogens; the field is evolving very
rapidly, and many pre-clinical and clinical studies are ongoing.
It has been shown that mRNA vaccines induce potent CD4+ and
CD8+ T-cell responses and, unlike the DNA-based vaccines, are
able to generate potent neutralising antibody responses in ani-
mals after only one or two doses. The main advantage of mRNA
vaccines is that they are synthesised in vitro and therefore do not
require growth in cell culture and can be produced rapidly at a
relatively low cost. However, recently published results from two
clinical trials on influenza and rabies mRNA vaccines showed a
lower response compared with what was expected from the pre-
clinical data (Pardi, Hogan and Weissman 2020).
Access to multiple genome sequences also provides data
on the strain-to-strain sequence variations of specific antigens,
allowing the design of recombinant antigens predicted to pro-
vide cross-protection against genetically diverse strains. Data on
strain-to-strain sequence variability, combined with the knowl-
edge of the three-dimensional structure and epitope mapping,
could guide the design of more stable, more immunogenic and
cross-reactive antigens. This multifactorial approach is the basis
of the ‘structural-vaccinology’ era, also referred to as ‘reverse
vaccinology 2.0’ (Rappuoli et al. 2016). The success of such an
approach was elegantly shown by the RSV (respiratory syncy-
tial virus) vaccine, based on a stable and strongly immunogenic
‘pre-F’ antigen (McLellan et al. 2013). The RSV F antigen consists
of two forms: pre- and post-fusion. The pre-fusion protein is
the antigenic form that mediates the fusion between the viral
capsid and the host cell membrane. Following the fusion, the
F capsid antigen undergoes a conformational change, assum-
ing an open structure (post-fusion). Antibodies with neutralis-
ing activity recognise the pre-fusion form of the protein and
block its interaction with the host cell receptor. When expressed
as a recombinant protein, the pre-fusion protein has an unsta-
ble conformation, which opens up, shifting its structure to
the post-fusion conformation. The introduction of two cysteine
residues in key positions allowed the formation of a disulphide
bond, which locks the F protein in its pre-fusion, and therefore
immunogenic, structure. This stabilised F protein induces neu-
tralising antibodies in humans of one order of magnitude higher
than the non-stabilised form. Clinical trials are ongoing, and
this approach is expected to deliver an effective RSV vaccine
in the near future. Additional RSV vaccine approaches include
adjuvanted formulations and mRNA (Higgins, Trujillo and Keech
2016).
One of the principles of the reverse vaccinology 2.0 is
based on the generation of human monoclonal antibodies from
convalescent or vaccinated subjects for the identification of new
protective antigens or for the mapping of protective epitopes.
This kind of approach has been successful in the identification
of the most protective cytomegalovirus antigen based on a pen-
tameric capsid antigen, which is under evaluation in pre-clinical
studies (Macagno et al. 2010).
The same approach has been used in the case of influenza
for the identification of a universal flu vaccine effective against
all subtypes of this virus (Krammer and Palese 2015). A cross-
reactive monoclonal antibody (mAb) was identified as being able
to recognise 16 different haemagglutinin (HA) subtypes. The
mAb mapped to a conserved epitope located on the stem of
the HA protein, the region that varies less frequently compared
with the head region of this protein. An influenza vaccine based
on the HA stem antigen was able to induce broadly neutral-
ising antibodies in an animal model (Nachbagauer et al. 2018).
Moreover, three monoclonal antibodies, isolated from a patient
infected with the influenza A H3N2 virus, were able to bind to the
neuraminidase active site, neutralising the virus across multiple
strains.
Finally, the advances in the field of immunology have allowed
the discovery of novel adjuvants, molecules that, when added
to vaccine antigens, are able to enhance its immunogenicity.
The need for adjuvants is particularly important for purified
recombinant antigens, which induce a lower immunogenicity
compared to live-attenuated or inactivated whole-cell vaccines,
which contain many immune-stimulatory components.
MF59, a squalene oil-in-water emulsion, is the adjuvant used
in the seasonal influenza vaccine, licensed for use in individ-
uals of 65 years and over. This adjuvant can induce recruit-
ment of inflammatory cells at the injection site, resulting in
increased antigen uptake and stimulation of adaptive immunity.
MF59-adjuvanted influenza vaccine showed higher efficacy than
the non-adjuvanted vaccine in preventing laboratory-confirmed
influenza and hospitalisations (Domnich et al. 2017). Adjuvant
systems are combinations of immunostimulatory molecules,
which have been recently licensed for adjuvanted vaccines
such as the papillomavirus vaccine containing AS04, an alu-
minium salt formulated with 3-odesacyl-4′-monophosphoryl
lipid A (MPL), a detoxified form of LPS extracted from Salmonella
minnesota; the influenza vaccine containing AS03, an oil-in-
water emulsion, containing squalene and α-tocopherol (vita-
min E) as an immunostimulant; and the malaria and the herpes
zoster vaccines containing AS01, composed of two immunos-
timulatory molecules, MPL and saponin QS-2, a triterpene gly-
coside purified from the bark extract of Quillaja saponaria Molina
(fraction 21) (Del Giudice, Rappuoli and Didierlaurent 2018). CpG
ODN, a soluble oligonucleotide TLR9 agonist and RC-529, a syn-
thetic glycolipid TLR4 agonist, are adjuvants for two commercial
hepatitis B vaccines, immune stimulating complexes (ISCOMs)
and Matrix M, based on phospholipid and cholesterol nanocom-
plexes and saponins, are the adjuvants for influenza vaccines
(Apostolico Jde et al. 2016). These adjuvants contributed to
enhancing the immune response significantly compared to non-
adjuvanted vaccines, in terms of antibody and cell-mediated
immunity, and efficacy and effectiveness.
CORONAVIRUS VACCINES
A safe and effective vaccine that is able to prevent disease, infec-
tion and spread of SARS-CoV-2 is urgently needed. The cur-
rent COVID-19 pandemic represents a clear example on how
the new technologies can drive vaccine design quickly and
effectively (Fig. 2). Immediately after SARS-CoV-2 was identi-
fied as the infectious agent, and the genomic sequence made
available, the search for vaccines and therapeutics was initi-
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Table 1. COVID-19 vaccines in clinical studies.
Manufacturer Vaccine type Antigen Clinical stage
Sinovac Inactivated Killed virus Phase III
Sinopharm/Wuhan Institute of
Biological Products
Inactivated Killed virus Phase III
Sinopharm/Bejing Institute of
Biological Products
Inactivated Killed virus Phase III
University of Oxford/Astrazeneca Non-replicating adeno
vector
ChAdOx1–5 Phase III




Adeno virus Type 5 Vector Phase III
Gamaleya Research Institute Non-replicating adeno
vector
rAd26-S + rAd5-S Phase III
Jannsen Pharmaceutical Companies Non-replicating adeno
vector
Ad26COVS1 Phase III
Pfeizer/BioNTech RNA LNP encapsulated mRNAs Phase III
Interim analysis 95%
efficacy
Moderna/NIAID RNA LNP encapsulated mRNA—S Phase III
Interim analysis 94.5%
efficacy
Curevac RNA mRNA Phase III
Novavax Protein sub-unit S nanoparticle Matrix M
adjuvant
Phase III
Sanofi Pasteur/GSK Protein sub-unit S + AS03 adjuvant Phase III





Protein sub-unit Trimeric S + adjuvant Phase II/III
Israel Institute for Biological
Research/Weizmann Institute of
Science
Replicating viral vector VSV-S Phase II
Arcutus/Duke RNA mRNA Phase II
Inovio Pharmaceuticals/International
Vaccine Institute
DNA DNA with electroporation Phase II
Osaka University/AnGes/Takara Bio DNA DNA + adjuvant Phase II
Cadila Healthcare Limited DNA DNA Phase II
Genexine Consortium DNA DNA Phase II
Anhui Zhifei Longcom
Biopharmaceutical/Institute of
Microbiology, Chinese Academy of
Science
Protein sub-unit RBD-dimer + adjuvant Phase II
Bharat Biotech Inactivated Killed virus Phase I/II
Institute of Medical Biology, Chinese
Academy of Medical Science
Inactivated Killed virus Phase I/II
Research Institute for Biological Safety,
Republic of Kazakhistan
Inactivated Killed virus Phase I/II
Beijing Minhai Biotechnology Inactivated Killed virus Phase I/II
Kentucky Bioprocessing Protein sub-unit RBD Phase I/II
SpyBiotech/Serum Institute of India Virus-like particles RBD-HBsAg VLPs Phase I/II
ImmunityBio, Inc. & Nantkwest, Inc. Non-replicating Adeno
vector
hAd5 S + second-generation




Simian adenovirus-S Phase I
Cansino Biologicals, Inc./Institute of




Ad5-nCov (IM and mucosal) Phase I
Vaxart Non-replicating adeno
vector
Ad5-adjuvanted oral Phase I
Ludwig Maximilians University of
Munich
Non-replicating vector MVA-SARS-2-S Phase I





Replicating viral vector Measles-vector based Phase I
Beijing Wantal Biological
Pharmacy/Xiamen Univeristy
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Table 1. Continued
Manufacturer Vaccine type Antigen Clinical stage
Imperial College London RNA LNP-nCovsaRNA Phase I
People Liberation Army Academy of
Military Science/Walvax Biotech
RNA mRNA Phase I
Symvivo DNA bacTRL-S Phase I
Oral
Vaxine Pty Ltd/Medytox Protein sub-unit S + Advax adjuvant Phase I
University of Queensland/CSL/Seqirus Protein sub-unit Molecular clamp stabilised




Protein sub-unit S-2P + CPG adjuvant Phase I
Instituto Finlay de Vacunas, Cuba Protein sub-unit RBD conjugated to tetanus
toxoid
Phase I
Instituto Finlay de Vacunas, Cuba Protein sub-unit RBD + adjuvant Phase I
FBRI SRC vb Vector, Koltsovo Protein sub-unit Peptide Phase I
West China Hospital, Sichuan
University
Protein sub-unit RBD Phase I
University Hospital Tubingen Protein sub-unit HLA-DR peptides
subcoutaneously
Phase I
Covaxx/United Biomedical, Inc., Asia Protein sub-unit Multiepitope-based RBD Phase I
S: spike protein, RBD: receptor binding domain; HBsAg: hepatitis B antigen; VSV: vesicular stomatitis virus; LNPs: lipid nanoparticles; bacTRL: bacterial vector in
probiotic bacteria.
large pharmaceutical companies have started to share data and
to cooperate. As of November 2020, more than 200 candidate
vaccines have been proposed and 47 are being tested in clin-
ical studies (Table 1, https://www.who.int/publications/m/ite
m/draft-landscape-of-covid-19-candidate-vaccines). The main
approaches include killed inactivated virus, viral vectors, virus-
like particles, DNA, RNA and sub-unit vaccines. The mRNA vac-
cine developed by BioNTech/Pfeizer was shown to be 90% effec-
tive in preventing COVID-19 infection in the first interim analy-
sis of a Phase III study conducted on 43 538 subjects. Results of
the Phase III studies with the mRNA Moderna vaccine showed
it to be 94.5% effective. Additional candidate vaccines that are
expected to enter a clinical trial in 2020 are based on the same
technologies described above and include alternative delivery
routes, such as oral or intranasal.
Although it is not known how many of these vaccines will
show efficacy and persistence in humans, the major chal-
lenge will be to generate an extremely high number of doses
rapidly in order to vaccinate the global population, at least
those that are defined as populations at risk. In practice, it
is likely to be necessary to license more than a single vac-
cine. One possibility for improvement is the use of an adju-
vant for the sub-unit-based vaccines. The addition of an adju-
vant such as Matrix M, AS03, MF59 or CPG could increase
the immune response at a lower antigen dose, resulting in
the availability of a much higher number of vaccine doses.
Adjuvants are easy to manufacture and are expected to pro-
vide a solution for a response to a rapidly evolving global
emergency.
CONCLUSIONS
There is no doubt that vaccines have made an enormous con-
tribution to the health and well-being of humanity and have
shaped civilisation profoundly over the last century. However,
challenges remain and the COVID-19 pandemic has shown that
we cannot be complacent in the face of infectious disease
and the ongoing need for effective vaccines against aggressive
pathogens. For much of the later half of the 20th century, and
up to December 2019, most populations, especially in high-
income countries, were not seriously and universally threatened
by infectious disease. This situation saw a dramatic change in
2020. The impact of COVID-19 on public health, as well as its
economic and socio-political impact, has already changed the
world and reminded us of the dangers we face when a deadly
disease spreads and there is no effective intervention. The voice
of anti-vaccine activists can still be heard on social media, but
for the many it is a reminder of the value of vaccines and vacci-
nation to our way of life.
The race for a COVID-19 vaccine is now at full speed with, at
the time of writing, half a dozen or so candidates entering the
later stages of clinical trials. Several of these, and many more in
the pre-clinical pipeline, are harnessing new technologies, for
example, those based on vector platforms recently developed to
address SARS-1, MERS, Ebola and Zika outbreaks, or on recom-
binant proteins or the use of RNA or DNA. Others use more
traditional approaches, relying on precedence to reduce the risk
of failure. The scientific community has responded in earnest
to the challenge and the pace of development is impressive.
Guidance from regulators is needed to reduce the risk of adverse
reactions and to ensure these efforts are successful. The design
and development of an effective vaccine against SARS-CoV-2 is
a challenge, but one that is based on a sound knowledge of the
structure, function and immunobiology of related pathogens
and a broad collective experience of vaccine development.
Vaccination schedules of each and every country have also to
be taken into consideration as both demographics and available
vaccines will vary between countries. The global health com-
munity can be optimistic that at least one and probably several
of the approaches will provide an effective vaccine, although
the dangers of antibody-dependent enhancement and/or
vaccine-enhanced respiratory disease cannot be dismissed.
The development of a successful vaccine must be followed by
a successful programme of manufacturing, distribution and
vaccination. This will require an unprecedented scale-up of
the successful technologies to produce the billions of doses of
vaccine required, and their equitable and timely distribution
throughout the world. Most of the technologies leading the race
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is uncertain whether they can deliver the quantities so desper-
ately needed. As and when the supplies become available, the
rollout and distribution of vaccine will require careful manage-
ment and international support and good will based on effective
and cooperative global politics. Apart from all these logistical
issues, equity of access to vaccine has to be a high priority.
Yet, this situation raises additional questions: Who will own
the vaccine? How to get it to those who need most? How can
trials be ethically fast-tracked? There is no doubt that vaccine
safety is as important as vaccine efficacy, urging the need for
intensive safety studies both in the development phase and
post-marketing, and then in larger population-based settings.
Furthermore, while there is a large amount of focus on a possi-
ble COVID-19 vaccine, it is also important not to neglect routine
immunisation programmes that protect people against vaccine-
preventable diseases. There are additional challenges in deliver-
ing routine vaccination when health resources are directed else-
where, as well as the difficulty or reluctance to visit doctors or
places where vaccination takes place (such as schools). Utilising
the vaccines that are already available is crucial in order to avoid
other disease outbreaks on top of COVID-19. Moreover, when we
eventually arrive in the post-COVID-19 era, world leaders must
resolve to never allow this happen again by ensuring signifi-
cantly strengthened R&D support for vaccine development and
other infectious disease interventions and, in particular, generic
effective future pandemic preparedness, as this is the funda-
mental basis of a strong public and global health architecture.
Conflict of interest. None declared.
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